Cardiovascular Safety of the ß<sub>3</sub> -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial.

Cardiovascular Safety of the ß₃ -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial.

White, William B; Chapple, Christopher; Gratzke, Christian; Herschorn, Sender; Robinson, Dudley; Frankel, Jeffrey; Ridder, Arwin; Stoelzel, Matthias; Paireddy, Asha; van Maanen, Robert; Weber, Michael A.

Afiliação

White WB; Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA.
Chapple C; Royal Hallamshire Hospital, University of Sheffield, Sheffield, UK.
Gratzke C; Department of Urology, University of Munich, Munich, Germany.
Herschorn S; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Robinson D; King's College Hospital, London, UK.
Frankel J; Seattle Urology Research Center, Seattle, WA, USA.
Ridder A; Department of Data Science, Astellas Pharma Global Development, Leiden, Netherlands.
Stoelzel M; Department of Data Science, Astellas Pharma Global Development, Leiden, Netherlands.
Paireddy A; Department of Data Science, Astellas Pharma Global Development, Leiden, Netherlands.
van Maanen R; Department of Data Science, Astellas Pharma Global Development, Leiden, Netherlands.
Weber MA; Division of Cardiovascular Medicine, State University of New York Downstate Medical Center, Brooklyn, NY, USA.